Carl L. Gordon Sells 3,571,428 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock

Compass Therapeutics, Inc. (NASDAQ:CMPX) Director Carl L. Gordon sold 3,571,428 shares of the firm’s stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Compass Therapeutics Trading Up 2.7 %

Shares of CMPX traded up $0.05 during midday trading on Friday, hitting $1.70. The stock had a trading volume of 650,759 shares, compared to its average volume of 856,141. The business has a 50-day simple moving average of $2.59 and a two-hundred day simple moving average of $2.10. The firm has a market cap of $234.39 million, a P/E ratio of -4.58 and a beta of 1.40. Compass Therapeutics, Inc. has a fifty-two week low of $0.77 and a fifty-two week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CMPX has been the topic of several analyst reports. Guggenheim reaffirmed a “buy” rating and issued a $12.00 target price on shares of Compass Therapeutics in a research report on Wednesday, April 2nd. HC Wainwright boosted their target price on Compass Therapeutics from $10.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, April 4th. Leerink Partners raised shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $4.00 to $6.00 in a report on Wednesday, April 2nd. Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 1st. Finally, Piper Sandler began coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $13.38.

Institutional Trading of Compass Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company acquired a new position in Compass Therapeutics during the third quarter valued at $79,000. XTX Topco Ltd acquired a new position in shares of Compass Therapeutics in the 3rd quarter valued at about $37,000. Barclays PLC lifted its position in shares of Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after purchasing an additional 112,614 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Compass Therapeutics by 0.8% during the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after purchasing an additional 19,095 shares during the period. Finally, SG Americas Securities LLC grew its position in Compass Therapeutics by 921.6% during the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after purchasing an additional 356,352 shares in the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.